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What's already known about this topic?  
There is a strong genotype–phenotype link in atopic dermatitis (AD) patients suffering from 
filaggrin (FLG) haploinsufficiency, but acquired FLG deficiency can also occur in AD 
patients. It is not known whether the clinical and laboratory characteristics of AD are 
influenced only by genetic or also by acquired FLG alterations. 
What does this study add? 
1. Actual skin barrier impairment in AD patients with severe skin inflammation is similar in 
FLG wild-type patients and FLG mutants and correlate with the severity of skin inflammation 
(SCORAD). 
2. On the other hand the constant barrier deficiency in filaggrin mutants results in an 
increased risk of allergic sensitisation compared to wild-type patients. 
 
Summary 
Background: Filaggrin (FLG) deficiency is a well-known predisposing factor for the 
development of atopic dermatitis (AD). Decreased FLG expression can be the result of 
haploinsufficiency or severe inflammation, which can cause acquired FLG alterations. FLG 
mutations are related to several clinical and laboratory parameters of AD; however, some 
recent data seem to contradict these associations. 
Objectives: Our aim was to determine which clinical and biochemical parameters are 
connected to FLG haploinsufficiency and which ones are also associated with acquired FLG 
alterations due to severe skin symptoms in AD patients.  
Methods: We introduced a novel classification of AD patients based on FLG mutations and 
SCORAD. Based on these parameters, we created three groups of AD patients: mild-to-
moderate wild-type (A), severe wild-type (B) and severe mutant (C) patients. In all groups, 
we assessed laboratory and clinical parameters and performed immunohistochemical 
analyses.  
Results: Groups B and C contained patients with equally severe symptoms based on the 
SCORAD. The two severe groups did not differ significantly with respect to barrier-specific 
parameters, whereas group A had significantly better results for the barrier function 
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measurements. However, significant differences were detected between groups B and C with 
respect to the allergic sensitisation-specific parameters.  
Conclusions: These findings suggest that skin barrier function correlates with the severity of 
skin inflammation and can be equally impaired in FLG mutant and wild-type AD patients 
with severe symptoms. Nevertheless, our results also suggest that FLG mutant patients may 
have a higher risk of allergic sensitisation compared to wild-type patients. 
 
Introduction 
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects up to 20% of the 
white European paediatric population1. AD is often accompanied by other allergic diseases 
(e.g., allergic rhinitis and bronchial asthma) and leads to an impaired quality of life2,3. 
Previously, the development of AD was primarily explained by the dysregulation of immune 
responses (the inside-out theory); however, in the last few years, the role of skin barrier 
alterations has been emphasised (the outside-in theory)4-6. 
The filaggrin (FLG) protein, which is produced from the profilaggrin precursor and is located 
in the granular and corneal layers of the skin, plays a pivotal role in the formation of the skin 
barrier6,7. Active FLG plays a major role in crosslinking keratin filaments and participates in 
the development of the cornified envelope, and its degradation products are important 
components of natural moisturising factors (NMFs)8,9. NMFs buffer the pH of the skin and 
play a role in UV protection (e.g. urocanic acid), as well as in immunomodulation10-12. 
Intragenic variation with respect to the copy number of FLG monomers is correlated with the 
occurrence of AD, and the presence of fewer FLG repeats in the profilaggrin gene contributes 
significantly to the development of AD13. 
Previous investigations have demonstrated that major (R501X and 2282del4) as well as 
minor (S3247X, R2447X and 3702delG) FLG null mutations are responsible for the 
development of ichthyosis vulgaris (IV), and these mutations are also major predisposing 
factors for AD14,15. Recently, several research groups have reported associations between 
FLG mutations and the severity of AD, early disease onset, allergic sensitisation, the 
frequency of eczema herpeticum outbreaks and the degree of skin barrier defects, which are 
characterised by high transepidermal water loss (TEWL)16-18. However, others have not 
detected any correlations between FLG mutations and TEWL, skin diffusion or permeability, 
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and suggest that FLG haploinsufficiency may play a minor role in the barrier abnormalities 
characteristic of AD19, or attribute this contradiction to low patient numbers10. We suggest 
that this discrepancy may result from the fact that until now, most studies investigating the 
effects of FLG haploinsufficiency have not taken into consideration the SCORAD (SCORe 
Atopic Dermatitis) value as an independent parameter to differentiate the compared groups. 
Patients without FLG mutations (wild-type) can also suffer from severe AD, and the actual 
severe skin inflammation (high SCORAD) can lead to FLG reduction and alter barrier 
functions. 
In the current investigation our aim was to study whether acquired FLG deficiency as a 
consequence of actual skin inflammation can result in the same barrier disruption as FLG 
mutations. Therefore, we established three patient groups (mild-to-moderate and severe wild-
type and severe mutant) and systematically analysed and compared the most frequent AD-
related clinical (SCORAD, TEWL, patients’ atopic history) and laboratory parameters (serum 
thymic stromal lymphopoietin [TSLP] levels, total and specific IgE levels) among these 
groups, as well as FLG content and epidermal thickness, which were measured after 
immunohistochemical staining. Of great importance, our results clearly identified the 
parameters that are mainly related to FLG genotype and those that are also associated with 
the severity of skin inflammation. 
 
Materials and methods 
Patients 
Peripheral blood was obtained from 49 Caucasian AD patients, 22 males and 27 females 
(mean age: 19 years, range: 5–36 years) with mild-to-moderate or severe clinical symptoms. 
Skin biopsy specimens were also collected from six patients. All patients suffered from 
extrinsic type of AD. Their mean total IgE serum level was 3370 kU/L, mean objective 
SCORAD (OSCORAD) was 31.51, mean LDH was 436.9 U/L, and mean eosinophil count 
was 0.49 G/L. Patients with AD did not suffer from any concomitant skin diseases at the time 
of the examination and had not been treated with any moisturisers for 1 day, topical 
corticosteroids for 3 days or with systemic immunosuppressants for 28 days prior to 
examination. The following laboratory parameters were examined: serum TSLP level, total 
IgE and specific IgE levels (house dust mites, ragweed and cat dander). Data on the patients’ 
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history of other allergic diseases and sensitisation were recorded. The severity of AD was 
determined using OSCORAD (Objective SCORe Atopic Dermatitis) and was also checked 
by measuring epidermal thickness in biopsy specimens. Three groups were formed according 
to their FLG status and clinical severity: Group A, patients with mild-to-moderate AD 
symptoms (OSCORAD ≤ 25) without FLG mutations (n=10); Group B, patients with severe 
AD symptoms (OSCORAD > 25) without FLG mutations (n=22); and Group C, patients with 
severe AD symptoms (OSCORAD > 25) who carried FLG mutations (n=17, of which 15 
were heterozygotes for one of the two alleles [11 patients for 2282del4 and 4 patients for 
R501X], and two were compound heterozygotes). The compound heterozygous patients 
belonged to the severe FLG mutant group, and they had no concomitant IV. Healthy controls 
(n=10) were included as the basis for the comparison of barrier function and serum TSLP 
levels. All participants provided written informed consent according to the principles of the 
Declaration of Helsinki. The study was approved by the local ethics committee. 
 
Filaggrin genotyping 
Analysis of the FLG mutations R501X and 2282del4 was performed for all patients. DNA 
isolated from peripheral blood mononuclear cells using the GenElute Blood Genomic DNA 
Kit (Sigma, Chemical Co., St. Louis, MO, USA) was subjected to polymerase chain reaction 
(PCR) amplification. Primers for genotyping were ACG TTC AGG GTC TTC CCT CT and 
ATG GGA ACC TGA GTG TCC AG for R501X; CAG TCA GCA GAC AGC TCC AG and 
AAA GAC CCT GAA CGT CGA GA for 2282del4. PCR amplification conditions were as 
follows: 1 cycle of 95°C for 5 minutes; 35 cycles of 95°C for 30 seconds, 64°C for 30 
seconds, and 72°C for 30 seconds; and 1 cycle of 72°C for 10 minutes. All PCR products 
were purified using a QIAquick PCR Purification Kit (Qiagen, Inc) and bidirectionally 
sequenced on an ABI Prism 3100 automated sequencer with Big-Dye terminator cycle 
sequencing reagents (Applied Biosystems, Foster City, CA) as previously described21.  
Measurement of TEWL 
Measurements were performed under standardised laboratory conditions at a temperature of 
22–25 ˚C and a humidity level of 40–60%. Before the measurements were taken, patients 
were allowed to adapt to the room conditions for 5 minutes. TEWL measurements (g/hm2) 
were carried out with Tewameter TM300 (Courage and Khazaka, Cologne, Germany) on 
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nonlesional and lesional skin on both forearms, from the cubital fossa down to the wrist. The 
duration of the measurements, performed in triplicate, was 30 seconds.  
Immunohistochemical staining and whole-slide imaging 
For immunohistochemical analyses, paraffin-embedded sections from lesional AD skin (two 
patients from each group were selected randomly, giving six samples altogether), and healthy 
controls (n=2) were deparaffinised using xylene and ethanol. Heat-induced antigen retrieval 
was performed using citrate/TRIS buffer, and sections were preprocessed with H2O2 for 5 
minutes, followed by the blocking of endogenous peroxidase activity and nonspecific binding 
sites for 15 minutes. Sections were stained with an antibody against human filaggrin (mouse 
IgG: Abcam, Cambridge, UK). Subsequently, anti-mouse polyclonal antibodies from the 
Dako Real EnVision Detection System kit (Dako, Glostrup, Denmark) were employed. 
Staining was detected using the Vector VIP Kit (VECTOR Laboratories, Burlingame, CA). 
Sections were counterstained with methylene green. The slides were digitalised using a 
Pannoramic SCAN digital slide scanner with a Zeiss plan-apochromat objective 
(magnification: 20X, Numerical aperture: 0.8) and Hitachi (HV-F22CL) 3CCD progressive 
scan colour camera (resolution: 0.2325 μm/pixel). Epidermal thickness as a well-accepted 
method for the measurement of the severity of skin inflammation in AD20 and 
immunostainings were analysed with Pannoramic Viewer 1.15.2 (3DHistech Ltd., Budapest, 
Hungary), using the HistoQuant application. Regions of interest (ROIs) (n=20/slide) were 
selected in the corneal layer, and then the Field area [FA (mm2)] and the Mask area [MA 
(mm2)] were calculated by the software. The FA shows the whole area of the ROI, and the 
MA represents the filaggrin-positive area. The MA/FA values were calculated for all ROIs. 
 
TSLP ELISA  
Serum was isolated from patients and aliquoted, and the TSLP levels were determined using 
the ELISA Human TSLP Quantikine Immunoassay according to the manufacturer’s 
instructions (R&D Systems, Minneapolis, MN). 
 
Statistical analysis 
To determine the statistical significance of the results, the Kruskal-Wallis test and the Mann-
Whitney test were used to analyse nonparametric distributions, and Fisher’s exact test was 
applied to compare specific IgE values and the history of sensitisation. P-values <0.05 were 
considered statistically significant (*p<0.05; **p<0.01; ***p<0.005). 
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Results 
Skin barrier dysfunction and serum TSLP levels are elevated in severe AD patients 
irrespective of FLG genotype 
When comparing the OSCORAD of each patient group, significant differences were observed 
between the mild-to-moderate (Group A) and severe groups (Groups B and C) (P<0.0001). 
Comparison of the severe FLG wild-type (Group B) with the severe FLG mutant group 
(Group C) revealed no significant difference in their OSCORAD levels (Fig. 1a).  
Then, TEWL was measured on nonlesional (Fig. 1b) and lesional AD skin (Fig. 1c). 
Significantly increased TEWL was observed in the severe groups (Group B, and C) relative 
to the mild-to-moderate group (Group A) for both nonlesional skin (P=0.0100 and P=0.0262, 
respectively) and lesional skin (P=0.0234 and P=0.0464, respectively). No difference was 
detected between the two severe groups (Groups B and C) with respect to TEWL for either 
the lesional or the nonlesional skin. When determining serum TSLP levels in the three AD 
groups, no significant difference in serum TSLP levels was detected between the mild-to-
moderate group and the severe groups. When combining all severe patients into one group, 
significant elevation of serum TSLP levels was observed in severe patients compared to 
healthy controls (P=0.0236) (Fig. 1d).  
Importantly, TEWL measured for nonlesional skin (Fig. 1e) and lesional skin (Fig. 1f) 
showed a strong correlation with the OSCORAD score (P=0.0063, Spearman’s rho=0.48 for 
nonlesional skin and P=0.0029, Spearman’s rho=0.61 for lesional skin). 
Allergic sensitisation is associated with FLG haploinsufficiency 
In contrast to the barrier measurements, for which the two severe groups had similar results, 
our data indicate that the level of allergic sensitisation differed between the two severe 
groups. The occurrence of allergic asthma and rhinitis in the personal medical history of the 
patients was detected significantly more frequently in the FLG mutant group (P=0.0166 and 
P=0.0154) than in the wild-type groups (groups A and B, respectively) (Fig. 2a). With respect 
to the levels of serum total IgE (Fig. 2b), a three-level tendency was observed. Prominent 
differences were found between the severe groups (groups B and C) and between the wild-
type groups (P=0.0181). In addition, a significant difference was found between groups A 
and C (P=0.0229) (Fig. 2B). These distinctions appeared even stronger when measuring 
specific IgE levels for ragweed (Fig. 2c) and cat dander (Fig. 2d) in AD patients; indeed, 
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significant differences were observed between the mutant and the wild-type groups 
(P=0.0090 and P=0.0472 for ragweed and P=0.0338 and P=0.0021 for cat dander in groups A 
and B and groups B and C, respectively). No significant differences were found between 
groups B and C with respect to the specific IgE levels for house dust mites (Fig. 2e). 
 
Epidermal FLG content changes equally in severe AD patients with and without FLG 
mutations 
Beside the SCORAD, skin inflammation was also detected by measuring epidermal 
thickness, and the two severe groups (B and C) showed significantly increased acanthosis 
compared to group A (P<0.0001) (Fig. 3f). Reduced or no FLG staining was observed in the 
skin of severe AD patients, in both FLG mutants (Fig. 3c) and wild-type patients (Fig. 3b). 
Normal FLG immunostaining was found in the upper granular layer and the lower corneal 
layers of the epidermis of the normal controls (Fig. 3d) and AD patients with mild-to-
moderate symptoms (Fig. 3a). When the FLG content was measured using the HistoQuant 
analysis software, a significantly lower FLG level was observed in AD skin biopsies relative 
to samples from normal controls (P=0.0001 for mild-to-moderate, and P<0.0001 for severe 
groups). In addition, there were significant differences between group A and groups B and C 




AD is a multifactorial disease that is driven by different genetic and environmental factors. 
Crucial events that have been identified in the development of the disease22,23 are overactive 
adaptive and dysregulated innate immune responses and also impaired skin barrier function. 
One basic component of the physicochemical barrier is FLG, which may show genetic 
alterations (e.g. FLG null mutations and copy number variations in Caucasian AD patients), 
or acquired damage due to the effects of cytokines produced by T helper (Th) cell subtypes 
(Th2 and Th22) in AD24-26. Other barrier gene mutations (KLK7, SPINK5, Claudin-1) may 
also predispose to AD, although the occurrence of these alterations against the background of 
disease development is still not clearly known27-29. Acquired barrier disruption can also be 
caused by the frequent usage of detergents, as well as allergens and toxic mediators; however, 
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up to now only Th2 and Th22 cytokines have been confirmed to modify FLG expression30. 
FLG haploinsufficiency exhibits one of the strongest genotype–phenotype associations with 
the clinical and laboratory characteristics of AD, but recent studies are not consistent 
concerning the link between FLG mutations and skin barrier parameters.  
In this study, our aim was to determine whether actual severe skin inflammation can cause as 
severe barrier defects as genetic FLG alterations, which clinical and laboratory parameters 
are associated with FLG haploinsufficiency, and which ones are also associated with acquired 
FLG alterations. 
In order to answer this specific question, a novel subdivision of AD patients was introduced 
in this study. Based on actual disease severity, defined by the OSCORAD, and on the FLG 
genotype, we created three patient groups (wild-type patients with mild-to-moderate 
symptoms or severe symptoms – Groups A and B; and mutant patients with severe symptoms 
– Group C). Using this system, we were able to investigate two groups suffering from severe 
symptoms (B, C) but differing in their FLG genotype, and two groups with a wild-type FLG 
genotype (A, B) but with different SCORAD values. Therefore, we were able to determine 
which investigated parameters are related to the actual severe skin inflammation (which is 
responsible for the acquired FLG alterations) and which are related to the FLG genotype. 
Previous studies suggest that minor FLG mutations (S3247X, R2247X and 3702delG) are 
less prevalent in continental Europe than in the United Kingdom and Irish populations6, and 
in a larger German cohort were present in <1%7. Therefore our patients were genotyped for 
the two most common loss-of-function mutations (R501X and 2282del4), for the first time in 
the Hungarian population. We do not believe that the exclusion of the minor variants would 
have altered our findings significantly.  
In our study, significant differences in TEWL were found between the mild-to-moderate and 
severe groups for both nonlesional and lesional skin areas whereas no differences were 
observed between the two severe AD groups irrespective of their FLG genotype. This 
observation emphasises that beside genetic FLG haploinsufficiency, actual disease severity 
can also greatly influence barrier functions, as also supported by the strong correlation 
between the OSCORAD and TEWL. 
In the last few years, measuring TEWL has become the most acceptable noninvasive way to 
examine skin barrier alterations in AD patients31,32. Certain groups have found significant 
differences in TEWL between AD patients with and without FLG haploinsufficiency33,34; 
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however, others could not confirm these results10,20. The reason for this contradiction could 
be that in those studies in which an association between the FLG genotype and TEWL was 
detected, the SCORAD values also differed between patient groups; whereas when no 
differences were found between the above-mentioned groups, the SCORAD values were 
almost the same, so the effect of SCORAD on TEWL was not calculated. 
The importance of measuring TSLP levels in patients suffering from AD has also increased 
remarkably in the last few years. Elevated TSLP levels in the lesional skin are highly 
characteristic of AD, although the direct association between AD severity and TSLP 
expression in the epidermis has not yet been clarified35. Significant elevation of serum and 
stratum corneum TSLP levels was also detected in AD patients, and the expression in the 
stratum corneum correlated with disease severity36-38. On the other hand one workgroup 
failed to detect elevated serum TSLP levels in AD patients39. In our study, serum TSLP levels 
did not differ significantly among the three AD groups, although TSLP levels in the sera of 
the mild-to-moderate group were lower than those of the severe wild-type group. In a 
comparison of the serum TSLP levels of the combined severe and mild-to-moderate AD 
group with the TSLP levels of healthy controls, only the severe group showed significant 
elevation, providing further data regarding the previously mentioned unsolved contradiction 
in the literature. In summary, the skin barrier functions (measured by TEWL on both 
nonlesional and lesional skin) were influenced equally by a hereditary lack of FLG and by 
acquired FLG insufficiency, driven by severe skin inflammation. 
To demonstrate that actual skin inflammation (measured by OSCORAD and epidermal 
thickness) is strongly linked with FLG alterations in AD patients, immunohistochemical 
staining of skin biopsies was also performed. Similar to the TEWL and TSLP results, FLG 
expression was not detected or was significantly decreased in both severe groups, irrespective 
of the origin of the FLG deficiency40. 
In contrast to barrier functions, allergic sensitisation was mainly associated with FLG 
haploinsufficiency. The medical history data, which indicated the occurrence of other allergic 
diseases, the serum total IgE levels, as well as the presence of specific IgE against ragweed 
and cat dander, differed prominently between the mutant and wild-type patient groups. These 
indicators of allergic sensitisation were remarkably more frequent in the mutant group. The 
reason for this difference could be that hereditary FLG deficiency results in continuous 
disruption of the skin barrier over the whole lifespan, whereas acquired FLG deficiency, 
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which is the result of actual skin inflammation, fluctuates and is not continuously present. 
Regarding levels of specific IgE against house dust mites no differences were found between 
the distinct genotype groups. The reason for this difference could be that a shorter duration of 
skin inflammation and barrier impairment is sufficient to sensitise individuals against this 
aggressive allergen, which is not just extremely frequent, but has prominent proteolytic 
activity that induces inflammatory responses. 
Our results are consistent with those of recent studies that showed that allergic rhinitis, 
eosinophilic esophagitis and traceable specific IgE against cat dander were more frequently 
present in AD patients with FLG mutations than in wild-type patients30,41. 
In summary, our results show that in AD patients with severe skin inflammation, the skin 
barrier can be disrupted as much in FLG wild-type patients as in FLG mutants and correlates 
with the severity of skin inflammation (SCORAD). In contrast, our results also suggest that 
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Figure legends 
Figure 1. Comparison of skin barrier functions and serum TSLP levels in subgroups of 
AD patients. No difference was found between the severe groups with respect to the 
OSCORAD, although the mild-moderate group had significantly lower values (P<0.0001) 
(1a). Significant TEWL elevation (for both nonlesional skin (1b) – P=0.0100, P=0.0262, and 
lesional skin (1c) P=0.0234, P=0.0464) was observed in the severe groups relative to the 
mild-moderate group. In the three-group-subdivision, no significant difference in serum 
TSLP levels was detected between the mild-to-moderate group and the severe groups. When 
combining all severe patients into one group, a significant increase in serum TSLP levels was 
observed in the severe groups compared to the healthy control group (P=0.0236) (1d). A 
strong correlation was found between TEWL and the OSCORAD score for nonlesional (1e) 
and lesional (1f) skin. 
Figure 2. Occurrence of allergic sensitisation-specific parameters in subgroups of AD 
patients. Significant differences were found between the severe mutant and wild-type 
patients (P=0.0166 between group A and group C, and P=0.0154 between group B and group 
C) when analysing the data on patient history (2a). A remarkable difference was detected in 
the level of total IgE between the severe groups, and significant differences were found 
between the severe and mild-moderate groups (P=0.0181 between group A and group B, and 
P=0.0229 between group A and group C) (2b). With respect to the ragweed-specific (2c) and 
cat dander-specific (2d) IgE levels, significant differences were observed between the severe 
groups and between the severe mutant and mild-moderate groups (P=0.0090 and P=0.0472 
This article is protected by copyright. All rights reserved. 
for ragweed; P=0.0338 and P=0.0021 for cat dander in groups A and B and groups B and C, 
respectively). No differences were found between the severe groups in the occurrence of 
house dust mite-specific IgE (2e). 
Figure 3. Immunohistochemistry and whole-slide imaging of FLG in skin biopsies from 
healthy controls and AD patients. FLG immunostaining was performed for mild-to-
moderate patients (3a), severe wild-type patients (3b), severe mutant patients (3c) and healthy 
controls (3d). A significantly lower FLG content was observed in the AD skin biopsies 
relative to the biopsies of the normal controls (P=0.0001 for mild-to-moderate, and P<0.0001 
for severe groups). There were also differences between group A and groups B and C 
(P=0.0010 and P=0.0036, respectively) (3e). Scale bar = 100 μm. The epidermis was 
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